MODIFICATION
B -- Evaluation of Risk of Narcolepsy/Pandemrix
- Notice Date
- 7/11/2012
- Notice Type
- Modification/Amendment
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2012-N-14596
- Archive Date
- 8/24/2012
- Point of Contact
- Berta L Biltz,
- E-Mail Address
-
bbiltz@cdc.gov
(bbiltz@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- The Centers for Disease Control and Prevention (CDC), contemplates entering into a contract with the Brighton Collaboration in Switzerland to conduct an extension of a scientific study to further evaluate the association between particular brands of the services to be acquired for the "Enhanced Evaluation of Risk of Narcolepsy Associated with Pandemrix and Arepanrix" project are the scientific and technical expertise and administrative capability to build upon the multi-country European CDC coordinated study (through VAESCO) to further assess the risk of narcolepsy following vaccination with Pandemrix, Arepanrix and potentially other adjuvanted and non-adjuvanted H1N1 vaccines in European and other non-European countries. The Brighton Collaboration is a global network dedicated to vaccine safety research with the mission to bring countries together to conduct vaccine safety research and support other vaccine safety initiatives. We are seeking to leverage an ongoing study in Europe conducted by the Brighton Collaboration to extend the current European study to gather additional data to better evaluate the condition of interest (risk of narcolepsy after receipt of Pandemrix and expanding to evaluate Arepanrix [Canada]). To the best of our knowledge, the Brighton Collaboration has been the primary contractor for the European study since the start of the study including planning, writing and implementing the study protocol they are uniquely situated to support our goal of enhancing the current study and enroll other countries to gain a better understanding of the current European findings. Therefore, it is considered to be the only source that can satisfy this requirement. The anticipated period of performance shall be two years from date of award. All questions/concerns about the RFP shall be submitted via e-mail to BBiltz@cdc.gov. The solicitation will be available for downloading when issued, approximately on July 26, 2012. It is your responsibility to keep up with additional postings regarding the RFP on the Fedbizopps Website. See Numbered Note 22.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2012-N-14596/listing.html)
- Place of Performance
- Address: Europe, Switzerland
- Record
- SN02799553-W 20120713/120711235503-f8c5546f6be15bf27f213abce4f68aa5 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |